256 related articles for article (PubMed ID: 34641742)
1. An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus.
Novodvorský P; Haluzík M
Expert Opin Drug Saf; 2022 Mar; 21(3):349-361. PubMed ID: 34641742
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.
Visolyi GÁ; Domján BA; Svébis MM; Péterfi A; Lovász BD; Mészáros S; Horváth VJ; Tabák ÁG
Can J Diabetes; 2023 Jun; 47(4):368-377. PubMed ID: 36963632
[TBL] [Abstract][Full Text] [Related]
3. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
[TBL] [Abstract][Full Text] [Related]
4. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
Giorgino F; Caruso I; Napoli R
Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
[TBL] [Abstract][Full Text] [Related]
5. Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
Risovic I; Dumanovic MS; Bojic M; Djekic D
BMC Endocr Disord; 2023 Feb; 23(1):28. PubMed ID: 36726134
[TBL] [Abstract][Full Text] [Related]
6. Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.
Lisco G; De Tullio A; Guastamacchia E; Triggiani V
Endocr Metab Immune Disord Drug Targets; 2021; 21(4):626-646. PubMed ID: 32628602
[TBL] [Abstract][Full Text] [Related]
7. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.
Blonde L; Anderson JE; Chava P; Dendy JA
Curr Med Res Opin; 2019 May; 35(5):793-804. PubMed ID: 30370783
[TBL] [Abstract][Full Text] [Related]
8. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
Blumer I; Pettus JH; Santos Cavaiola T
Postgrad Med; 2018 May; 130(4):375-380. PubMed ID: 29521173
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes.
Perreault L; Rodbard H; Valentine V; Johnson E
Adv Ther; 2019 Feb; 36(2):265-277. PubMed ID: 30610613
[TBL] [Abstract][Full Text] [Related]
10. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
Goldman J; Trujillo JM
Ann Pharmacother; 2017 Nov; 51(11):990-999. PubMed ID: 28645216
[TBL] [Abstract][Full Text] [Related]
11. Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes.
Østergaard L; Frandsen CS; Dejgaard TF; Madsbad S
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):621-632. PubMed ID: 28349716
[TBL] [Abstract][Full Text] [Related]
12. Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
Wilding JP; Bain SC
Diabet Med; 2016 Jul; 33(7):864-76. PubMed ID: 26525806
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Basal Insulin/GLP-1 Receptor Agonist Used in Combination for Type 2 Diabetes Management.
McCarty D; Olenik A; McCarty BP
J Pharm Pract; 2019 Dec; 32(6):671-678. PubMed ID: 29566586
[TBL] [Abstract][Full Text] [Related]
14. Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.
Mehta R; Billings LK; Liebl A; Vilsbøll T
Diabet Med; 2022 Sep; 39(9):e14901. PubMed ID: 35708737
[TBL] [Abstract][Full Text] [Related]
15. Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.
Forst T
Expert Opin Pharmacother; 2016 Aug; 17(12):1703-8. PubMed ID: 27341040
[TBL] [Abstract][Full Text] [Related]
16. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes.
Harris K; Nealy KL
Ann Pharmacother; 2018 Jan; 52(1):69-77. PubMed ID: 28799414
[TBL] [Abstract][Full Text] [Related]
18. Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
Ferrannini E; Niemoeller E; Dex T; Servera S; Mari A
Diabetes Obes Metab; 2022 Jun; 24(6):1159-1165. PubMed ID: 35257461
[TBL] [Abstract][Full Text] [Related]
19. Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge.
Kaneto H; Koshida R; Baxter M
Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():24-34. PubMed ID: 32436323
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evaluation of fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes.
Lamos EM; Davis SN
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1225-32. PubMed ID: 27467569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
